Verapamil, an L-type calcium channel blocker, has been used successfully to treat cardiovascular diseases. Interestingly, we have recently shown that treatment of cancer cells with verapamil causes an effect on autophagy. As autophagy is known to modulate chemotherapy responses, this prompted us to explore the impact of verapamil on autophagy and cell viability in greater detail. We report here that verapamil causes an induction of autophagic flux in a number or tumor cells and immortalized normal cells. Moreover, we found that inhibition of autophagy in COLO 205 cells, via treatment with the chloroquine (CQ) or by CRISPR/Cas9-mediated disruption of the autophagy genes Atg7 and Atg5, causes an upregulation of apoptotic markers in response to verapamil. In search of a mechanism for this effect and because autophagy can often mitigate metabolic stress, we examined the impact of verapamil on cellular metabolism. This revealed that in normal prostate cells, verapamil diminishes glucose and glycolytic intermediate levels leading to adenosine 5 0 -triphosphate (ATP) depletion. In contrast, in COLO 205 cells it enhances aerobic glycolysis and maintains ATP. Importantly, we found that the autophagic response in these cells is related to the activity of L-lactate dehydrogenase A (LDHA, EC 1.1.1.27), as inhibition of LDHA reduces both basal and verapamil-induced autophagy and consequently decreases cell viability. In summary, these findings not only identify a novel mechanism of cytoprotective autophagy induction but they also highlight the potential of using verapamil together with inhibitors of autophagy for the treatment of malignant disease. 
Verapamil, an L-type calcium channel blocker, has been used successfully to treat cardiovascular diseases. Interestingly, we have recently shown that treatment of cancer cells with verapamil causes an effect on autophagy. As autophagy is known to modulate chemotherapy responses, this prompted us to explore the impact of verapamil on autophagy and cell viability in greater detail. We report here that verapamil causes an induction of autophagic flux in a number or tumor cells and immortalized normal cells. Moreover, we found that inhibition of autophagy in COLO 205 cells, via treatment with the chloroquine (CQ) or by CRISPR/Cas9-mediated disruption of the autophagy genes Atg7 and Atg5, causes an upregulation of apoptotic markers in response to verapamil. In search of a mechanism for this effect and because autophagy can often mitigate metabolic stress, we examined the impact of verapamil on cellular metabolism. This revealed that in normal prostate cells, verapamil diminishes glucose and glycolytic intermediate levels leading to adenosine 5 0 -triphosphate (ATP) depletion. In contrast, in COLO 205 cells it enhances aerobic glycolysis and maintains ATP. Importantly, we found that the autophagic response in these cells is related to the activity of L-lactate dehydrogenase A (LDHA, EC 1.1.1.27), as inhibition of LDHA reduces both basal and verapamil-induced autophagy and consequently decreases cell viability. In summary, these findings not only identify a novel mechanism of cytoprotective autophagy induction but they also highlight the potential of using verapamil together with inhibitors of autophagy for the treatment of malignant disease.
Macroautophagy (hereafter referred to more simply as autophagy) is a highly conserved catabolic process that mediates self-degradation of intracellular material. The main function of autophagy is to maintain cellular homeostasis by removing protein aggregates, damaged or spare organelles in a selective or nonselective manner [1] . In addition, the process can also provide macromolecules necessary for biosynthesis and ATP production, when cells are exposed to stress conditions [2] . Therefore, autophagy exists at a basal level in all living cells, but it can be elevated in response to various factors such as pathogen infections [3] , glucose [4] and amino acid starvation [5] , proteotoxic stress [6] , or in terms of cancer-chemotherapy [7] [8] [9] .
The main steps of autophagy are well characterized at the structural level, largely due to observations by transmission electron microscopy (TEM) [10] (Fig. 1) . The first observable structure in TEM is a hemispherical phagophore, known as a nucleation step during autophagosome (AP) formation [11] . The phagophore is formed de novo and membranes involved in phagophore assembly are most likely originated from specific ER subdomains-omegasomes or ER-mitochondria contact sites [12] . Yet lipids, in which the phagophore membrane is particularly enriched, might be delivered from different, already existing, proximal organelles [12] . Upon engulfing cellular contents, the phagophore starts to close up until the double-membrane AP structure is reached. AP is also often referred to as the early autophagic vacuole (AV). The formation of AP involves the rapid growth of the structure, which creates a need for additional source of membranes. Hence, other cellular compartments and organelles like ER-Golgi compartments, plasma membrane, or endosomes are also described as membrane suppliers [11] [12] [13] . In the next step, APs can fuse with late endosomes such as multivesicular bodies and form amphisomes, indicating the crossover between autophagy and endocytic pathways [14] . The amphisome is a hybrid structure and can be more acidic than AP due to late endosome content, which however, excludes active lysosomal enzymes. Consequently, for degradation to occur, amphisomes must fuse with lysosomes to form autolysosomes (ALs) [14] . APs can also attach directly to lysosomes and transform into single-membrane AL [15] . While the structure of the phagophore and the AP is not always easy to differentiate unless threedimensional TEM is applied, distinguishing between AP and AL is relatively straightforward. Firstly, there is a visible difference between double and single membranes and secondly, the content of AL is usually more degraded due to activity of lysosomal enzymes. AL is therefore often referred to as late, degradative AVs. Structures that are also often observed in cells undergoing autophagy are multilamellar bodies (MLB). The origin of these is not yet confirmed, but possibly they are formed from accumulation of phagophore membranes or they originate from selective degradation within ALs [16] (Fig. 1) .
At a molecular level, autophagy is regulated by several protein complexes such as mTORC1, ULK1, and Beclin1-VPS34 [17] . These control the products of numerous autophagy-related (Atg) genes, which orchestrate the initiation and progression of the process. For example, ATG5 and ATG7, as well as other ATG proteins, arrange a cascade of reactions leading to lipidation of light chain 3 (LC3), which in turn integrates into AP membranes and constitutes a well-characterized and easily detectable feature of autophagy [18] .
Autophagy has been implicated in several diseases among which cancer has recently attracted the attention of researchers. Autophagy appears to have dual roles in cancer. Firstly, it can play a cytoprotective role by eliminating aggregated proteins or damaged organelles at early stages of tumor formation [19] . Moreover, autophagy can also be tumor suppressive by reducing oxidative stress, delivering nucleotides for DNA replication and repair, or by contributing to cell death [20] . Autophagy is also regarded as an individual type of cell death termed autophagic cell death [17] . In many cases autophagy and apoptosis can share regulatory pathways including proteins such as Bcl-2, Bcl-X L , c-FLIP, caspase 3, tBid, Bad, PUMA [21] . In contrast, in advanced tumors, autophagy may support an oncogenic effect by preventing tumor cell death. Therefore, inhibition of autophagy often sensitizes cancer cells to cell death [21] .
Considering the possible implications of autophagy in tumor progression and cell death regulation, research is currently being undertaken toward autophagy modulation for therapeutic purposes. Some of the calcium channel inhibitors are reported to have a cytotoxic effect on cancer cells [22, 23] , however, their function is often not connected to calcium modulation. It is known, for example, that verapamil and other Ltype calcium channel blockers have an effect on glucose transport and metabolism in several cell types [24] . Cancer cells are often addicted to the glycolytic pathway because beyond the energetic profit, it enables them to accumulate a certain pool of intermediate metabolites to perform biosynthetic reactions. Therefore, cancer cells are sensitive to glucose levels and can upregulate autophagy once they are in shortage [25] .
Recently we showed that verapamil led to an accumulation of autophagy-like structures at the ultrastructural level in COLO 205 cells [26] . Here, we confirm that administration of verapamil induces autophagy flux in selected cell types. Moreover, we explore the relationship between autophagy and apoptosis in verapamil-treated cells and show that induced autophagy plays cytoprotective role in this context. Furthermore, we describe a new mechanism by which verapamil stimulates autophagy involving a switch toward aerobic glycolysis and enhanced lactate production. These rearrangements in cellular metabolism are frequently associated with tumor progression.
Results

Cytotoxicity of verapamil
The primary goal of this study was to understand the mechanism by which verapamil modulates autophagy and to determine how this affects the cytotoxicity of the drug. To this end, we analyzed the effects of verapamil in a series of human cell lines including colon adenocarcinoma COLO 205 cells, prostate cancer PC-3 cells and normal, immortalized prostate PNT-2 cells, pancreatic cancer KP-4 cells and normal, immortalized pancreatic HPNE cells as well as lung cancer H1299 and A549 cells and TIG3 primary lung fibroblasts. To investigate verapamil cytotoxicity, we used the 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide (MTT) assay as a cell viability indicator and the crystal violet assay as an index of cell proliferation.
We observed that in PC-3 ( 
Verapamil-treated cells present features of autophagy
To investigate the effects of verapamil on autophagy, we choose two cell lines, which were the most sensitive to verapamil treatment-COLO 205 and PC-3, and the one showing a relatively minor response-PNT-2 Fig. 1 . Schematic illustration of autophagy steps with identification of involved structures by TEM. Autophagy begins with the formation of phagophore membrane, which further enwraps cellular content and closes to form the double-membrane AP. The latter can fuse with a late endosome, forming an amphisome structure, or directly with the lysosome to progress into the single-membrane AL, in which degradation occurs. MLB are also visible in TEM and these can either contribute to the early or late steps of autophagy. (6, 12, 24, 48 h ). Two way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001. (6, 12, 24, 48 h ). Two way ANOVA; *P < 0.05; **P < 0.01; ***P < 0.001.
Multilamellar bodies
PNT-2 cells (Fig. 4K-L)
. Upon closer analysis of TEM micrographs of COLO 205 and PC-3 cells taken at different time points (6, 12, 24 h) after verapamil treatment, we observed dynamic development of autophagic structures involving both early and late AVs. Early AVs were represented by doublemembrane APs, surrounding cytoplasmic components and organelles. Additionally, late, degradative AVs constituting single-membrane ALs together with MLB, were also observed. Quantitation and statistical analysis of the number of AVs (APs and ALs) as well as the surface they occupied in relation to the cytoplasm, showed a highly significant increase after verapamil treatment in COLO 205 and PC3 cells (Fig. 5 ). Verapamil-treated PNT-2 cells also revealed rise of the AVs, however, both indicators were lower in comparison to COLO 205 and PC-3 cells (Fig. 5 ).
The effects of verapamil on autophagy were further confirmed by confocal microscopy via analysis of the conversion of the autophagy protein marker from LC3-I to LC3-II ( 
Verapamil induces autophagic flux
Accumulation of LC3-II positive puncta is considered one of the main characteristic markers of autophagy, however, this can represent induction as well as inhibition of the process at the stage of APs-lysosome fusion [27] . To distinguish between the two possibilities we conducted autophagic flux assays by western blotting, to compare accumulation of LC3-II upon treatment with verapamil, lysosomal protease inhibitors-E64d and pepstatin A (E64d/PepA)-, or the combination of these drugs (Fig. 7) . Although increased levels of LC3-II were visible upon E64d/PepA treatment, accumulation of LC3-II was greater after verapamil administration and following combined treatment with verapamil and E64d/PepA in all tested cell lines, although the concentration where the effect was observed varied between different cell lines ( Fig. 7A,E) . Interestingly, however, administration of E64d/PepA in PNT-2 cells did not affect LC3-II levels, suggesting that the basal autophagy in these cells is lower than in other cell lines. Of note, the levels of LC3-I can vary between cell lines and between experiments, and so a representative blot was chosen in each case which showed the highest clarity of changes in LC3-II. When taken together these data show that induction of autophagy occurs upon verapamil treatment, however, the absolute level of autophagy can differ between the cell lines.
Inhibition of verapamil-induced autophagy leads to enhanced apoptosis
In order to investigate the relationship between autophagy and cell death we choose to further examine COLO 205 cells as verapamil efficiently induces cytotoxic effects (Figs 2H and 3H) and autophagy ( Fig. 7E ) in these cells. COLO 205 cells were treated with the autophagy inhibitor, CQ in either the absence or presence of increasing concentrations of verapamil. After 24 h of treatment, we assessed cell death markers such as proteolytic cleavage of poly (ADP-ribose) polymerase (PARP) and cleavage of caspase 3 by western blotting (Fig. 8A ). This showed that verapamil alone (100, 200 lM) induced cell death as evidenced by the appearance of cleaved forms of both PARP and caspase 3. Moreover, we observed that the extent of both PARP and caspase 3 cleavage was even greater when verapamil was administered in combination with CQ. To confirm these findings, we inhibited autophagy in a different way by disrupting the essential autophagy genes Atg5 or Atg7 in COLO 205 cells using CRISPR/Cas9 technology. As can be seen in Fig. 8B , C, we successfully deleted Atg5 and Atg7, however, minor levels of the Atg5-12 conjugate were still visible following Atg5 disruption. This is likely due to a small percentage of cell population in the lentivirally infected pool that did not undergo CRISPR-mediated gene disruption. Importantly, administration of verapamil (100 lM) to cells with either Atg5 or Atg7 deletion, resulted in higher levels of cleaved PARP when compared to cells infected with a nontargeting sgRNA as control. Cytotoxicity of verapamil (200 lM) was also evidenced by decreased levels of actin-the loading control used in the experiments (Fig. 8A-C) . Similarly, with the highest concentration of verapamil, especially in the cells with deletion of Atg5 or Atg7, the levels of PARP were also affected, which might be related to the enhanced cell death and associated proteolysis.
We conclude that verapamil does not require functional autophagy to mediate its cytotoxic effects and that conversely, autophagy is actually involved in limiting verapamil-induced cytotoxicity in COLO 205 cells. Verapamil treatment induces cytoprotective autophagy, which if inhibited either at the later stages of autophagy (CQ) or at the initiation of autophagy (CRISPR/Cas9-mediated deletion of Atg5 or Atg7), leads to enhanced apoptotic death in these cells.
Verapamil alters metabolic pathways
As shown above, verapamil (50-200 lM) administration markedly affects cell viability and proliferation of the cancer cell lines tested and this is accompanied by the induction of autophagy. One of the possible mechanisms underlying these effects is the fact that verapamil has been shown to inhibit glucose transport into the cell [28] . To investigate this possibility, we picked the most responsive cancer cell line, COLO 205, and for comparison, PNT-2 cells, which are less sensitive to verapamil, for metabolic analysis. In order to detect intracellular levels of selected metabolic intermediates in cells treated with verapamil (100 lM, 6 h), liquid chromatography-mass spectrometry (LC-MS) was applied. Using this approach, we found that COLO 205 cells did not undergo significant changes in glucose (Glu) and glucose-6-phosphate (Glu-6P) levels upon verapamil treatment (Fig. 9A,B) . However, we observed a significant decrease in phosphoenolpyruvate levels followed by increased lactate production (Fig. 9C,D) , indicating that verapamil affects glycolysis downstream of glucose uptake. Interestingly, however, we also observed that the levels of ATP were not affected after verapamil administration of COLO 205 cells (Fig. 9E) . In contrast to these findings, LC-MS analysis of PNT-2 cells after verapamil administration, revealed a marked decrease in intracellular Glu levels that was accompanied by decreased levels of Representative images of the western blots are shown (upper panels) together with quantitation of the percentage of cleaved PARP (lower panels). Each performed experiment is presented as an individual data point set with mean (AESEM), significant differences were marked with asterisks; one way ANOVA; *P < 0.05, n = 3.
both PEP and lactate. In this case too, a significant decrease in ATP levels was observed ( Fig. 9A-E) .
Inhibition of lactate dehydrogenase A enhances apoptosis and impairs basal and verapamilinduced autophagy in COLO 205 cells
As autophagy is intrinsically connected to cellular metabolism, we reasoned that the metabolic switch we had observed toward enhanced glycolysis may be connected to the induction of autophagy caused by verapamil treatment. We observed that verapamil affects glycolysis in both COLO 205 and PNT-2 cells, but yet cell death and autophagy levels were much higher in COLO 205 cells in response to the drug. Interestingly, one clear difference between the two cell lines relates to the effects of the drug on lactate levels. In COLO 205 cells, verapamil causes a marked increase in lactate levels, whereas the drug causes a highly significant decrease in lactate in PNT-2. This encouraged us to consider that the induction of autophagy by verapamil may relate to modulation of lactate in these cells. As lactate production mainly results from the activity of L-lactate dehydrogenase A (LDHA, EC 1.1. Charts with statistical difference from control (CTRL) were indicated with asterisks; t-test (*P < 0.05;**P < 0.01;***P < 0.001), ns, not significant.
we examined the effect of an LDHA inhibitor, sodium oxamate (SO), which, as expected, significantly lowered lactate levels in COLO 205 (Fig. 10A) . Using MTT assays, we found that administration of SO when compared to vehicle control also caused a significant decrease in cell viability of COLO 205 cells either without or with application of verapamil (Fig. 10B) .
As shown by western blotting in Fig. 10C , addition of SO as well as verapamil enhanced the expression of apoptotic markers-cleaved PARP and cleaved caspase 3. Apoptosis was further stimulated when SO and verapamil were added together and even greater when SO and verapamil treatment was accompanied by inhibition of autophagy with CQ.
As we observed that blocking of verapamil-induced autophagy in COLO 205 led to increased apoptosis (Fig. 8) , we wanted to investigate how SO can contribute to this effect. To this end, we performed autophagy flux studies by western blot, which further revealed that application of SO lowered the levels of LC3-II under basal conditions and also following verapamil treatment (Fig. 10C) . These findings indicate that verapamil can induce autophagy via stimulation of lactate production. Moreover, we conclude that not only blocking of autophagy at the degradation step by CQ but also reduction in autophagy capacity by SO leads to enhanced apoptosis in COLO 205 cells.
Finally, to test whether other metabolic pathways are involved in verapamil-induced autophagy, we examined as part of autophagic flux assays, the activity of mTOR kinase (mTOR Complex 1), as measured by assessing phosphorylation of P70S6K at threonine 389 (p-P70S6K), and the activity of AMPK as indicated by its phosphorylation at threonine 172 (p-AMPK). When assayed by western blotting (Fig. 10C) , minimal p-P70S6K was detected in control, SO-treated or verapamil-treated cells, while AMPK was phosphorylated in all these conditions. This indicates that neither of these . Charts represent mean (AESEM) from n = 3 independent experiments with three replicates. All data has been normalized by 1000 of cells. Statistical difference from control (CTRL) was indicated with asterisks; t-test (onetailed) *P < 0.05. Cell viability after treatment with sodium oxamate (SO, 40 mM, 24 h) alone or in combination with verapamil (Ver; 100 lM; 24 h) measured by MTT assay (B). Data are expressed as % of initial control (% of untreated cells at the time point = 0), n = 2 independent experiments with eight replicates. Significant differences are indicated with asterisks; one way ANOVA; ***P < 0.001. Western blot analysis after treatment with sodium oxamate (SO; 40 mM; 24 h) alone or in combination with verapamil (Ver; 100 lM; 24 h) and with or without addition of Chloroquine (CQ; 10 lM; 24 h) (C). Cleaved PARP, p-P70S6K (Thr 389), P70S6K, p-AMPK (Thr 172), AMPK, LC3, and cleaved caspase 3 levels were assessed and actin was used as a loading control.
pathways are modulated following treatment with verapamil and/or SO indicating that they are unlikely to be the mediators of the effects of these drugs on lactate production, autophagy, or cell viability.
Overall, these data show that verapamil treatment enhances glycolysis leading to increased lactate production. This excess lactate can then cause an induction of autophagy, independently of AMPK and mTOR activity and autophagy serves to promote the viability of the cells.
Discussion
In the 1990s, verapamil was reported to exert cytotoxic effects in colon cancer cells in vitro and in vivo [29, 30] . More recently, the literature also refers to its cytotoxic properties [31, 32] , especially toward inhibition of multidrug resistance in various cancer cells [22, 33, 34] . In this study, we have checked the cytotoxicity of a concentration range of verapamil in a time-dependent manner in eight cell lines originating from different tissues, such as pancreas-HPNE (normal cells) and KP4 (tumor cells), lung-TIG3 (normal lung fibroblasts) and H199, A549 (tumor cells), prostate-PNT-2 (normal cells) and PC-3 (tumor cells) and colon adenocarcinoma COLO 205 cells. Through our analysis of these lines, we conclude that while some cells are more sensitive to verapamil, this is not exclusively a tumor cell versus normal cells effect.
Reports from our laboratory and others have also revealed that verapamil can have effects on autophagy [35, 36] , but how the drug exactly affects the process was not investigated. In this manuscript, we now definitively show that verapamil is an inducer of autophagy. We show this by ultrastructural studies (TEM) and LC3-II detection by confocal microscopy in COLO 205 and PC-3 cells and also by autophagy flux assays in these and additional cell lines-KP-4, HPNE. However, in stark contrast, these effects on autophagy were comparatively minor in verapamil-treated, normal prostate PNT-2 cells. While it is tempting to speculate that this difference relates to normal versus tumor cells, consistent with our conclusions regarding verapamil cytotoxicity, this was not true for cancer (KP-4) versus normal (HPNE) cells of pancreatic origin. What is clear, however, is that verapamil induces autophagy in some cells, but not others, indicating a selective effect. Additionally, even though the increase in LC3-II after verapamil treatment was evident in all cell lines tested, further accumulation of LC3-II upon combined treatment of verapamil and E64d/PepA was not visible in all cases. In this context, it was clear that autophagic flux was upregulated in PC-3 and KP-4 cells, detectable by comparison of verapamil (50 lM) AE E64d/PepA treatments and in PNT-2 cells when comparing LC3-II levels upon verapamil (100 lM) AE E64d/PepA. In contrast, a further increase in LC3-II after E64d/PepA application was not observed in verapamil-treated COLO 205 and HPNE cells. However, this may reflect selective susceptibility of the examined cells to lysosomal protease inhibitors due to differences in activity of these enzymes between cell lines. Interestingly, in the case of COLO 205, additional analysis of autophagy flux using CQ instead of E64d/PepA, revealed increased levels of LC3-II when verapamil was administered with CQ by comparison to verapamil treatment alone (Fig. 10C) . This fully confirms induction of autophagy flux by verapamil in COLO 205. In light of this, it is also possible that CQ is a more efficient inhibitor of autophagy flux than E64d/PepA. This issue is further discussed in "Guidelines for the use and interpretation of assays for monitoring autophagy" [37] , where it is shown, that for some cell lines, autophagy is more successfully blocked by using lysosomotropic alkalizing agents when compared to the use lysosomal protease inhibitors such as E64d/PepA. Importantly, we also report that induction of autophagy by verapamil can be cytoprotective. We show that in COLO 205 cells inhibition of autophagy either chemically (CQ) or genetically (CRISPR/Cas9-mediated disruption of Atg5 and Atg7) causes an increase in markers of apoptosis upon verapamil treatment. This is undoubtedly not the first example of an interplay between apoptosis and autophagy. On the one hand, reports have shown that efficient execution of apoptosis is dependent on autophagy. For instance, during the response to DNA damage, expression of the macroautophagy regulator DRAM-1 is necessary for p53-mediated cell death [38] . Frequently however, it is actually blockade of autophagy that promotes cell death, especially in response to anticancer therapeutics. For example, it was shown that in the presence of cisplatin, the esophageal cancer cell line EC9706 induces autophagy and that inhibition of autophagy in this context ceased cell growth and induced apoptosis [39] .
Efforts to modulate autophagy are an ongoing strategy for anticancer treatment. Anticancer therapies can lead to autophagy activation via, for example, ER stress induction, mTOR inhibition, or AMPK activation in multiple cancer types [40] . Conversely, chemical or genetic inhibition of autophagy is an even more attractive strategy as many clinical trials are currently ongoing with the autophagy inhibitor, CQ, in combination with classic chemotherapy agents such as cisplatin or bortezomib [40] . In this context, our observation that CQ and verapamil can increase apoptosis in COLO 205 cells, is of high importance for the application of the drug to treat cancer. It is worth noting, however, that the modulation of autophagy for therapeutic reasons should be performed with caution, since it may exert different effects depending on the tumor origin, stage of development, gene mutations, etc. In the mouse model of nonsmall cell lung cancer (NSCLC) Atg7 ablation did completely block tumor formation caused by Kras activation and p53 deletion. However, in mice with established tumors, deletion of Atg7 halted tumor progression and led to tumor cell death, before the damage of the healthy tissue [41] . These and other studies [42] , indicate that the role of autophagy in tumor development and cell death can be context-dependent and require further investigation.
One of the previously described mechanisms of the action of verapamil is related to lowering intracellular glucose levels. Verapamil was reported to retard glucose consumption in several cell types including mouse cardiac muscle HL-1 cells [43] and also, by inhibiting glucose transporter 1, in L929 mouse fibroblasts [28] . In addition, verapamil was also recently proposed to act on thioredoxin-interacting protein (TNIXP), thereby rescuing pancreatic b cell degradation in mouse models of diabetes [44] . The proposed utilization of verapamil in diabetes is currently in phase II of clinical trials (ClinicalTrials.gov Identifier: NCT02372253) and related population studies revealed that in blood serum of verapamil-treated diabetics glucose levels are reduced in comparison to nonverapamil users with diabetes [45] . In light of our studies, an examination of the role of autophagy in this context would certainly be worthwhile, especially since autophagy has been shown to contribute to b-cell viability [46] .
In our studies, we confirmed that verapamil can reduce intracellular glucose levels when administered to normal prostate PNT-2 cells. Levels of PEP, lactate, and ATP were also decreased, which may lead to the impeded viability of this cell line at later time points. It is also possible that following verapamil treatment of PNT-2 cells, glycolysis is aborted and other metabolic pathways are activated instead. Glucose can be redirected to the pentose phosphate pathway (PPP) which is a side branch of glycolysis promoting the biosynthesis of nucleotides and fatty acids [11] . The PPP shunt is also responsible for the antioxidant response because NADPH is generated by this pathway. This is then utilized to form reduced glutathione that is able to neutralize damage caused by reactive oxygen species [47] . This might be important since verapamil was previously reported to stimulate oxidative stress when used together with the proteasome inhibitor, bortezomib [36] . Activation of alternative metabolic pathways could, therefore, possibly explain the higher tolerance of PNT-2 cells to verapamil treatment.
In contrast, in COLO 205 cells which undergo an autophagic response, neither glucose nor ATP levels were significantly downregulated upon verapamil treatment. It seems likely that in these cells, glycolysis proceeded as normal in the initial steps of the process, however, in the final stages we observed a drop in PEP levels correlating with increased generation of lactate. This phenotype is akin to the "Warburg effect", which is considered a common feature of cancer cells, comprising high glycolytic rates followed by elevated lactate production [48] . Tumor cells can metabolize lactate as an energy source and transport lactate to adjacent cancer cells through monocarboxylate transporters. Shuttling lactate between cancer cells and stromal cells may induce a "Reverse Warburg Effect" while exchanging lactate between hypoxic and normo/ hyperoxic cells is known as metabolic symbiosis [49] [50] [51] . Accumulation of lactate in cancer cells can lead to the creation of lactic acidosis conditions, which is related to tumor progression, metastasis and increased cell survival [51] . In addition to these effects, we show that accumulation of lactate can also modulate autophagy. The ultimate production of lactate is regulated by LDHA, an enzyme responsible for converting pyruvate to lactate. Importantly, we found that inhibition of LDHA decreased both basal and verapamil-induced autophagy. In addition and in line with our findings that verapamil induced cytoprotective autophagy, we also observed that inhibition of LDHA reduced cell viability and induced expression of apoptotic markers. These findings, therefore, not only identify an interestingly new pathway of autophagy induction downstream of verapamil but they also highlight the potential of combining verapamil with autophagy inhibitors for the treatment of human cancer. 
Material and methods
Additional reagents
Verapamil chloride (Sigma-Aldrich, V4629), E64d (LKT Laboratories, St. Paul, MN, USA, E0003), Pepstatin A (Merck Millipore, Darmstadt, Germany, 516481), CQ (Sigma-Aldrich, C6620), Sodium oxamate (Sigma-Aldrich, O2751). Whenever indicated by the manufacturer, the reagents were dissolved as concentrated (1000 fold) stock solutions. The equivalent volume of vehicle (0.1% v/v) was added to nontreated cells (CTRL).
Transfections and infections
Amphotropic retroviral infections were prepared using Phoenix-MMULV system (https://web.stanford.edu/group/ nolan/_OldWebsite/tutorials/tutorials.html). Briefly, Phoenix Ampho cells were infected with retroviral expressing vector pBP-puro-GFP-LC3 using calcium phosphate precipitates as previously described [52] . Supernatant collected from infected Phoenix cells was then filtrated and transferred into plates with COLO 205 and PC-3 cells. Procedure was repeated twice for 24 h and then the virus containing medium was exchanged with a fresh growing medium for 24 h recovery. Cells were selected in puromycin (0.5 lgÁmL À1 , Gibco, A11138-03) containing media for 1 week.
COLO 205 cells with ablated Atg5 or Atg7 were generated using CRISPR/Cas9 system. Lentiviral infections were performed as amphotropic viral infections described above, but with 293T cells instead Phoenix Ampho cells. 
Cell viability assay -MTT
Cell proliferation assay-Crystal Violet
Cells grown on 96-well plates were fixed twice for 20 min with ice-cold methanol (75%, 100%) and stained with 0.2% crystal violet (Sigma-Aldrich, C3886) in 2% ethanol solution for 10 min (37°C, 5% CO 2 ). After incubation cells were gently washed by immersion in distilled water, air-dried, and DNA-bound dye was diluted in 1% SDS in ddH 2 O (BioRad, Polska, Warsaw, Poland, 161-0416). Absorbance was measured at 590 nm using multiplate reader Infinite M1000 PRO (TECAN).
Western blots
Cells were collected from Petri dishes and lysed on ice in buffer containing: 1% triton-X, 0.1% SDS, 50 mM HEPES pH 7.4, 150 mM NaCl, 100 mM NaF, 10 mM EDTA, 10 mM Na 4 P 2 O 7 , protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany, 04693116001) for 30 min. After centrifugation (10 000 g, 5 min) protein levels were quantified with Bradford assay using solution of commercial Bradford reagent (Bio-Rad 500-0006) (1 : 4 v/v) in water. Samples containing equal amounts of protein (20 lg) were separated by SDS/PAGE and transferred to PVDF membranes. After blocking in 5% skimmed milk in TBST (NaCl 137 mM, KCl 2. 
Immunofluorescence
For confocal microscopy observations, cells previously infected with pBP-puro-GFP-LC3 plasmid were grown on coverslips and fixed in 4% paraformaldehyde for 15 min at RT. After washing in PBS coverslips were mounted on slides using immunofluorescence mounting solution (Dako, Glostrup, Denmark, CS70330) containing 0.5 lgÁmL À1 DAPI. Observations were made with Zeiss confocal microscopy (ZEISS, Jena, Germany) under a 609 objective with a 488 nm excitation laser to view GFP-LC3 positive puncta.
TEM observations
For ultrastructural studies, cells were fixed in 2.5% paraformaldehyde and 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 2 h at 4°C, following postfixation in 1% OSO 4 for 1 h. Subsequently cells were dehydrated in a series of increasing concentrations of ethanol up to 100% and embedded in Epon 812 resin. Next, material was cut into ultrathin sections and imposed on a copper grid and stained with uranyl acetate and lead citrate. Observations and photographs were made using JEOL JEM 1011 transmission electron microscope with camera MORADA (JEOL Ltd., Tokyo, Japan).
Metabolic analysis
Metabolomics studies were carried out using LC-MS as described before [42] . Cells were grown on six-well plates, washed three times for 5 min with PBS and metabolites were extracted at 4°C by gentle shaking for 10 min in icecold extraction solution (50% methanol, 30% acetonitrile, 20% milliQ water). After spinning (13 000 g, 10 min), supernatants were transferred into glass vials and stored in À80°C. To separate metabolites, we used Thermo Scientific Accela liquid chromatography system. For LC separation a ZIC-pHILIC column (Merck Millipore) was used with a gradient elution solution (20 mM ammonium carbonate, 0.1% ammonium hydroxide and acetonitrile). For metabolites detection, Thermo Scientific Exactive high-resolution mass spectrometer with electrospray (ESI) ionization was used. Results obtained from LC-MS were normalized to protein levels in samples measured with Lowry assay using commercial compound (Sigma-Aldrich, L3540).
